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ttp://dx.doi.org/10.1016/j.ajpath.2014.07.026Proliferative vitreoretinopathy (PVR) is a nonneovascular blinding disease and the leading cause for
failure in surgical repair of rhegmatogenous retinal detachments. Once formed, PVR is difﬁcult to treat.
Hence, there is an acute interest in developing approaches to prevent PVR. Of the many growth factors
and cytokines that accumulate in vitreous as PVR develops, neutralizing vascular endothelial growth
factor (VEGF) A has recently been found to prevent PVR in at least one animal model. The goal of this
study was to test if Food and Drug Administrationeapproved agents could protect the eye from PVR in
multiple animal models and to further investigate the underlying mechanisms. Neutralizing VEGF with
aﬂibercept (VEGF Trap-Eye) safely and effectively protected rabbits from PVR in multiple models of
disease. Furthermore, aﬂibercept reduced the bioactivity of both experimental and clinical PVR vitreous.
Finally, although VEGF could promote some PVR-associated cellular responses via VEGF receptors
expressed on the retinal pigment epithelial cells that drive this disease, VEGF’s major contribution to
vitreal bioactivity occurred via platelet-derived growth factor receptor a. Thus, VEGF promotes PVR by a
noncanonical ability to engage platelet-derived growth factor receptor a. These ﬁndings indicate that
VEGF contributes to nonangiogenic diseases and that antieVEGF-based therapies may be effective on a
wider spectrum of diseases than previously appreciated. (Am J Pathol 2014, 184: 3052e3068; http://
dx.doi.org/10.1016/j.ajpath.2014.07.026)Supported by NIH grant EY022970 (A.K.) and the Mukai Fund of the
Massachusetts Eye and Ear Inﬁrmary (Boston) (S.M.).
Disclosures: None declared.Proliferative vitreoretinopathy (PVR) occurs in 5% to 10%
of eyes after surgical repair of rhegmatogenous retinal
detachment (RD); in cases of RD arising from severe ocular
traumadsuch as penetration of the ocular globedthe inci-
dence can be as high as 50%.1e4 PVR remains the prevalent
obstacle to successful surgical outcome, accounting for
nearly 75% of all surgical failures.5e7 Because of this, ap-
proaches to reduce its incidence are greatly needed.
PVR occurs when cells are dispersed into the vitreous cavity
after a breach of the retina. These cells proliferate, generate
extracellular matrix, and coalesce into an epiretinal membrane
(ERM) capable of contracting and redetaching the retina.4,8e10
Growth factors and cytokines in vitreous act on the displaced
cells to reduce their level of TP53, thereby boost their ability to
resist apoptosis and senescence; such a mechanism explains
how these cells can thrive and promote pathological features in
the vitreous environment.11e14 These principles, whichstigative Pathology.
.emerged from studies with cultured cells and animal models,
are in agreement with recent genome-wide association studies
that show a predisposition to PVR in patients with particular
polymorphisms in the genes encoding the TP53 protein and its
upstream negative regulator Mdm2.15e17
Efforts to identify vitreous growth factors and cytokines
that drive PVR pathogenesis indicated that there is a long
list of candidates, and that platelet-derived growth factors
(PDGFs) are particularly notable because of their abun-
dance.18 However, despite the concordance between the
presence of PDGFs in vitreous and development of PVR,
and the requirement for PDGF receptor a (PDGFRa) in
experimental disease,19e22 PDGFs are dispensable for
VEGF Acts via PDGFRa to Promote PVRpathology. Instead, PDGFRa is activated indirectly by
vitreal growth factors and cytokines outside of the PDGF
family (non-PDGFs).22e24 These non-PDGFs drive an in-
direct mode of PDGFRa activation that circumvents re-
ceptor down-regulation (internalization and degradation)
mediated by PDGF, thereby perpetuating PDGFRa activa-
tion.12 In cells harboring indirectly activated PDGFRa, the
level of TP53 declines precipitously compared with the null/
modest TP53 decline observed for cells in which PDGFRa
has been activated directly.12 Thus, vitreous contains more
than one class of PDGFRa agonist, and, more important,
non-PDGFs are the key agonist driving PVR pathogenesis.
The presence of multiple classes of PDGFRa agonist in
PVR vitreous begs the question of how they functionally
interact to inﬂuence the bioactivity of vitreous.21,24e27 PDGF
prevents the indirect activation of PDGFRa by assembling
receptors into dimers, which are poorly activated by non-
PDGFs.12,14,28 If PDGFs and non-PDGFs were the only
agents inﬂuencing activation of PDGFRa, then PVR would
never develop because the non-PDGFs are held in check by
PDGFs. However, we recently reported that vascular endo-
thelial growth factor (VEGF) A (herein referred to as VEGF)
promotes the nonePDGF-dependent mode of activating
PDGFRa by antagonizing PDGF-mediated dimerization of
PDGFRs.28 Thus, there are three classes of growth factors
(PDGFs, non-PDGFs, and VEGF) in PVR vitreous, which
are engaged in functional interactions that determine the
activation state of PDGFRa (Figure 1).
Figure 1 shows that VEGF enables nonePDGF-driven
activation of PDGFRa and, therefore, predicts that VEGF is
an Achilles heel of PVR. Indeed, we recently reported that
neutralizing VEGF with ranibizumab mitigated the bioac-
tivity of vitreous and prevented PVR in an animal model of
this disease.14 In light of the translatability of this discovery,
and because existing PVR prophylactic therapies are few and
frequently ineffective,18 we tested the efﬁcacy and safety of
additional Food and Drug Administrationeapproved drugs
to prevent PVR using multiple animal models. Herein, we
report that aﬂibercept (trade name Eylea; Regeneron, Tar-
rytown, NY) safely and effectively protected rabbits fromFigure 1 The bioactivity of proliferative vitreoretinopathy (PVR) vitre-
ous depends on three classes of growth factors: vascular endothelial growth
factor (VEGF), platelet-derived growth factor (PDGF), and non-PDGFs
(growth factors outside of the PDGF family). The scheme shows the func-
tional relationship for these growth factors and the signaling events and
cellular responses triggered by indirectly activated PDGFRa. VEGF competi-
tively inhibits PDGF-dependent activation of PDGFRa. This direct mode of
activating PDGFRa antagonizes the indirect mode of activating PDGFRa,
which is driven by non-PDGFs. Indirectly activated PDGFRa promotes TP53
reduction, a key event in driving PVR, because TP53 suppression promotes
the viability of cells displaced into the vitreous and also mediates the
contraction of PVR membranes formed from these cells; both outcomes are
likely to contribute to retinal detachment.18
The American Journal of Pathology - ajp.amjpathol.orgsuccumbing to PVR. Furthermore, aﬂibercept reduced the
bioactivity of PVR vitreous isolated from experimental ani-
mals and patient donors. The results of these preclinical
studies reinforce the emerging idea that anti-VEGF therapy
may potentially apply as a prophylaxis for clinical PVR.
Materials and Methods
Biological Agents and Major Reagents
All antibodies, neutralizing agents, and human recombinant
growth factors and cytokines used in this study are detailed in
Table 1. Aﬂibercept/VEGF-Tr, a dimeric, recombinant
fusion glycoprotein comprising portions of the VEGFR1 and
VEGFR2 extracellular domains fused to the Fc region of
human IgG1, was used as the VEGF neutralizing agent in all
experiments. Human IgG1, added at an equimolar concen-
tration to aﬂibercept, was used as the isotype-matched con-
trol. All growth factors/cytokines, except PDGF-D, were
combined at their mean PVR vitreous concentrations and
used directly to treat cells as part of growth factors PVR.
Recombinant human PDGF-C, PDGF-D, hepatocyte
growth factor (HGF), insulin-like growth factor (IGF)-1, and
connective tissue growth factor (CTGF) were used as stan-
dards to quantify the level of their respective rabbit orthologs
in experimental vitreous by using Western immunoblot
analysis (quant-IB); all other growth factor/cytokine quanti-
ﬁcation was performed by multiplex assays (see Multiplex
Analysis).
All growth factor/cytokine antibodies used in this study,
including those in multiplex assays, detect and neutralize
human and rabbit orthologs equally well; this was deter-
mined, where necessary (ie, cross-species reactivity was not
evident from analysis of shared epitope sequences, the
literature, or technical manuals), by pilot experiments. The
VEGFR tyrosine kinase inhibitor II (VR-Inh) was obtained
from Calbiochem (San Diego, CA; catalog number 676481),
and blocks both VEGFR1 and VEGFR2 kinases (inhibitory
concentration of 50% of 180 and 20 nmol/L, respectively).
To ensure that both VEGFR kinases were completely
inhibited by the time treatment was administered, cells were
pretreated for 30 minutes with inhibitor, and added at a ﬁnal
concentration of 360 nmol/L.
Experimental PVR Models
PVR was induced in the right eyes of outbred composite
pigmented rabbits [retinal pigment epithelium (RPE)-injec-
tion model, purchased from Robinson Services Inc.,
Mocksville, NC] or Dutch-belted rabbits (ﬁbroblast-injec-
tion model, purchased from Millbrooke, Rockland, MA), as
previously described.14,19,24,29e31 In brief, rabbits were
acclimated for 1 week, anesthetized, and then injected with
0.1 mL of perﬂuoropropane gas (Alcon, Fort Worth, TX)
into the vitreous cavity 3 to 4 mm posterior to the
limbus. After 1 week, rabbits were anesthetized and each3053
Table 1 Antibodies, Neutralizing Agents, and Growth Factors/Cytokines Used in This Study
Agent Type/use Source Target Effective dose* Producer Notes
Aﬂibercept sR-Decoy Engineered VEGFs A-E, PlGF 40 mg/mL (0.9 mg) Regeneron y
a-PDGF-AB nAb Human PDGFs A, AB, B Per manuf. Millipore
a-PDGF-C nAb, quant-IB Human PDGF-C 1:2000 serum Ab ZymoGenetics (Seattle, WA) 21
a-PDGF-D nAb, quant-IB Human PDGF-D Per manuf. R&D Systems (Minneapolis, MN)
a-CTGF nAb, quant-IB Goat CTGF (see Notes) 200 ng/mL Santa Cruz Biotechnology
(Santa Cruz, CA)
24
sEGFR sR-Decoy Engineered EGF, TGF-a 4 mg/mL R&D Systems 27
a-FGF-2 nAb Mouse FGF-2 (bFGF) Per manuf. R&D Systems
a-G-CSF nAb Rabbit G-CSF Per manuf. Millipore
a-HGF nAb, quant-IB Goat HGF Per manuf. R&D Systems
a-IFN-g nAb Mouse IFN-g Per manuf. Millipore
a-IGF-1 nAb, quant-IB Mouse IGF-1 Per manuf. Millipore
a-IL-6 nAb Mouse IL-6 Per manuf. Millipore
a-MCP-1 nAb Rabbit MCP-1 Per manuf. Millipore
a-TGF-b nAb Rabbit TGF-bs (see Notes) Per manuf. R&D Systems Detects b1-3
a-TP53 IB-Ab Mouse TP53 250 ng/mL Cell Signaling (Beverly, MA)
a-RasGAP IB-Ab Rabbit RasGAP 1:5000 Serum Ab Kazlauskas Lab
a-VEGFR2 IB-Ab Mouse VEGFR2 100 ng/mL Cell Signaling
a-pVEGFR2 IB-Ab Rabbit Phospho-VEGFR2 200 ng/mL Cell Signaling
HRP-a-IgG Secondary Ab Goat Primary IB-Abs Per manuf. Santa Cruz
Isotype IgGs Control Ab Human NA 52 mg/mL (1.2 mg) Santa Cruz z
VEGF GF Human VEGFR 1/2, PDGFRs 2e50 ng/mL NCI Repository
PDGF-A GF Human PDGFRa 2e50 ng/mL PeproTech (Rocky Hills, NJ)
PDGF-AB GF Human PDGFRs a and ab 2e50 ng/mL PeproTech
PDGF-B GF Human PDGFRs 2e50 ng/mL PeproTech
PDGF-C GF, quant-IB Human PDGFRs a and ab 2e50 ng/mL R&D Systems
PDGF-D GF, quant-IB Human PDGFRb, (-ab) 2e50 ng/mL R&D Systems
CTGF GF, quant-IB Human M6P, TrkA, others? 2e50 ng/mL PeproTech
EGF GF Human EGFR, HER2/3 5e50 ng/mL PeproTech
FGF-2 GF Human FGFR-1 2e50 ng/mL PeproTech
G-CSF GF Human G-CSF-R 5e75 ng/mL PeproTech
HGF GF, quant-IB Human c-Met 2e50 ng/mL PeproTech
IFN-g GF Human IFN-gR 0.5e25 ng/mL PeproTech
IGF-1 GF, quant-IB Human IGFR-1, IR 2e50 ng/mL PeproTech
IL-6 GF Human IL-6R 0.2e10 ng/mL NCI Repository
MCP-1 GF Human CCR2 10e100 ng/mL PeproTech
TGF-a GF Human EGFR 5e50 ng/mL PeproTech
TGF-b1 GF Human TGF-bR 2e20 ng/mL PeproTech
TGF-b2 GF Human TGF-bR 2e20 ng/mL PeproTech
TGF-b3 GF Human TGF-bR 2e20 ng/mL PeproTech
All growth factor and cytokine antibodies used in this study detect both human and rabbit orthologs.
*Values pertain to in vitro dosing, with the exception of values in parentheses, which indicate in vivo dosing amounts (ie, for intravitreal injections in
experimental models).
yAﬂibercept is a fusion protein consisting of the extracellular domains of VEGFRs 1 and 2.
zAmount used is equimolar to experimental treatment (with aﬂibercept).
GF, recombinant human growth factor/cytokine; HRP, horseradish peroxidase; IB-Ab, Western immunoblot analysis antibody; Per manuf., set according to
manufacturer’s instructions; nAb, neutralizing antibody; PlGF, placenta growth factor; quant-IB, antibody used in quantitative Western immunoblot analysis or
ligand used as a puriﬁed standard in quantitative Western immunoblot analysis; sR-Decoy, soluble receptor decoy (also considered ligand traps).
Pennock et alexperimental eye was injected with 2.5  105 ARPE-19a
cells (RPE-injection model) or 2  105 rabbit conjunctival
ﬁbroblasts (RCFs; ﬁbroblast-injection model) in 0.1 mL
platelet-rich plasma (PRP) and 0.1 mL of balanced salt
solution containing either 0.88 mg aﬂibercept (a dose
equivalent to 2.0 mg in humans, as determined by inter-
species dose extrapolation32) or an equimolar amount of
isotype-matched control IgG1 (IgG). The PRP, obtained
from rabbits immediately before injection, is thought to3054emulate the intravitreal plasma inﬂux that accompanies
traumatic PVR in humans and is used to enhance the
severity and consistency of pathological features in these
models.19 Because of the longer time course used for the
RPE-injection model (49 days, compared with 28 days for
the ﬁbroblast-injection model), rabbits were injected again
on day 21 with aﬂibercept/IgG. Left eyes were not injected.
Retinal status was monitored using an indirect ophthalmo-
scope (Keeler Instruments, Broomall, PA) ﬁtted with aajp.amjpathol.org - The American Journal of Pathology
VEGF Acts via PDGFRa to Promote PVR30-diopter fundus lens (Volk Optical, Mentor, OH) at days 1,
3, 5, and 7, and once per week thereafter until the end of the
experiment (day 49 for RPE-injection model, day 28 for
ﬁbroblast-injection model). Fundus photography was per-
formed using the iPhone 5 (Apple, Cupertino, CA) and a 30-
diopter lens, as previously described.33 Intraocular pressures
were monitored daily for 3 days after gas injection and for 1
day after the coinjections using a Tono-Pen (Reichert Tech-
nologies, Depew, NY). PVR was graded using the Fastenberg
5-stage scale34: stage 0, no observable disease; stage 1, pres-
ence of an ERM; stage 2, ERM with focal retinal traction;
stage 3, localized RD of one to two quadrants; stage 4,
extensive RD of two to four quadrants without complete
detachment; and stage 5, complete RD. Signs of toxicity
during the experiment, including intraocular inﬂammation and
retinal hemorrhages, were assessed during each fundus ex-
amination. Two days before the end of each experiment,
electroretinograms (ERGs) were obtained from rabbits repre-
sentative of each treatment type (see below). At the end of the
experiment, rabbits were sacriﬁced, eyes were enucleated, and
then eyes were either ﬁxed in 10% formalin, embedded in
methacrylate, and divided into sections for histological anal-
ysis with hematoxylin and eosin (H&E), or frozen at 80C
for subsequent extraction of vitreous. All procedures were
performed aseptically and in pursuance with the Association
for Research in Vision and Ophthalmology Statement for the
Use of Animals in Ophthalmic and Vision Research. The
Schepens Animal Care and Use Committee approved the
protocol (S-349-0715) used for these animal experiments.
Electroretinography of Rabbits
Rabbit ERGs were obtained 2 days before the end of each
experiment, on the basis of the protocol of Duke et al.35
Retinal function was thoroughly assessed by obtaining
ERGs after scotopic ﬂash, photopic ﬂash, and photopic
ﬂicker modes of stimulation using the ColorDome stimulator
(Diagnosys, Westford, MA), and analyzing the a- and b-wave
components, as described previously.36e39 Three represen-
tative rabbits from aﬂibercept- or IgG-treated groups were
used to obtain ERGs. The noninjected contralateral eye was
measured to obtain reference readout for each rabbit.
Preparation and Use of Rabbit Vitreous
Vitreous was removed from frozen eyes, allowed to thaw to
room temperature, and then centrifuged at 4C for 5 minutes
at 10,000  g. The resultant clariﬁed vitreous was used for
subsequent analysis. Vitreous was from PVR-positive rabbit
eyes (RV-PVR), PVR-negative aﬂibercept-treated eyes
(RV-VTr), or healthy noninjected control eyes (RV). Half
the volume of each sample was set aside for quantitation
(see below). All vitreous used to treat cells is an equal-
volume mix from several (ﬁve or more) rabbit eyes of the
same PVR stage. Vitreous was diluted 1:1 in serum-free
medium immediately before using it for treatment.The American Journal of Pathology - ajp.amjpathol.orgCell Culture and Treatment
ARPE-19a cells are derived from the human retinal pigment
epithelial (RPE) cell lineARPE-19 (ATCC,Manassas, VA) and
made to overexpress human PDGFRa.21 Primary RCFs were
isolated as described previously.31 ARPE-19a and RCFs are
used in the RPE-injection model and ﬁbroblast-injection model
of PVR, respectively. RPEM cells are primary RPE cells iso-
lated from a human PVRmembrane surgically removed during
routine vitrectomy.40 RPEMs were used at low passage (4 to 8)
in experiments assessing the PVR bioactivity of human vitre-
ous. Primary human corneal ﬁbroblasts (HCFs) and primary
human umbilical vascular endothelial cells (HUVECs) were
used at low passage (4 to 9) alongside ARPE-19a and RPEMs
to compare and contrast mRNA expression of PDGFRa and
VEGFRs among RPE cells, ﬁbroblasts, and endothelial cells.
RCFs and HCFs were maintained in high glucose-
containing Dulbecco’s modiﬁed Eagle’s medium (DMEM;
Gibco BRL, Gaithersburg, MD) containing 10% fetal bovine
serum. ARPE-19a and RPEM cells were maintained in a 1:1
mixture of high-glucose DMEM and Ham’s F12 medium
(Gibco BRL) containing 10% fetal bovine serum. HUVECs
were maintained on collagen-coated plates in EGM-2 medium
(Clonetics; Lonza, Walkersville, MD) containing 10% horse
serum and 0.1% bovine brain extract (Lonza). All cells were
cultured in media supplemented with 500 U/mL penicillin and
500 mg/mL streptomycin, and incubated at 37C in a humid-
iﬁed 5% CO2 atmosphere.
For in vitro experiments involving Western blot analysis by
SDS-PAGE and immunoblot, near-conﬂuent cells were serum
starved overnight (minimum, 16 hours) and treated the next
morning. For treatments involving neutralizations and/or in-
hibitions, neutralizing agents/inhibitors were preincubated with
their targets in solution at the targets’ ambient temperature for 30
minutes before addition to cells.Cell treatmentswere performed
under the same conditions as cells cultured normally.
Quantiﬁcation of Growth Factors and Cytokines in
Experimental Vitreous
Vitreous isolated from experimental rabbits was analyzed
by multiplex or quantitative immunoblot, as previously
described.24Apanel of 26growth factors/cytokineswere chosen
for analysis on the basis of their association with PVR.18,24,41
These were VEGF, PDGF-A, PDGF-AB, PDGF-B, PDGF-C,
PDGF-D, CTGF, EGF, ﬁbroblast growth factor (FGF)-2,
granulocyte colony-stimulating factor (G-CSF), granulocyte-
macrophage (GM)-CSF, HGF, interferon (IFN)-g, IGF-1,
IL-1b, IL-6, IL-8, IL-9, IL-10, monocyte chemoattractant pro-
tein (MCP)-1, transforming growth factor (TGF)-a, TGF-b1,
TGF-b2, TGF-b3, tumor necrosis factor (TNF)-a, and TNF-b.
Quantitative Immunoblot
Quantitative immunoblot was performed, as previously
described,24 to measure the vitreous levels of PDGF-C,3055
Pennock et alPDGF-D, CTGF, HGF, and IGF-1 (for which the multiplex
platform is not yet available/feasible). Brieﬂy, vitreous was
sufﬁciently diluted (1:50 to 1:200, so as not to hinder
electrophoretic ﬂow of proteins) and run on 8% to 12%
SDS-PAGE gel alongside recombinant human growth factor/
cytokine standards of known concentration. Proteins were
transferred to polyvinylidene diﬂuoride membranes and
blotted with the appropriate detection antibodies (Table 1).
Signal intensity was determined by densitometry using
Quantity One (Bio-Rad, Hercules, CA) and growth factor/
cytokine concentrations interpolated on the basis of a standard
curve generated from the known concentrations of standards
run on the same gel. In some cases, membranes were stripped
and reprobed to quantifymultiple growth factors and cytokines
froma single gel. Atminimum, experimentswere performed in
quadruplicate to ensure acceptable quantitative accuracy.
Multiplex Analysis
Multiplex analysis of the remaining 21 growth factors/cyto-
kines was performed, as previously described,24 using two
different immunoassay kits: one to quantify the three TGF-b
isoforms (in their activated state) and the other customized to
quantify the remaining 19; both kits were purchased from
Millipore (Billerica, MA). Immunoassays were performed on
the basis of the manufacturer’s instructions for each kit, and as
previously described.24 Brieﬂy, each vitreous sample (50 mL)
was added in triplicate to a 96-well plate and then incubated
overnight with a mixture of monoclonal antibodyecoated
capture beads. Beads were washed and incubated with biotin-
labeled anti-human polyclonal growth factor/cytokine anti-
bodies for 1 hour, and then streptavidin-phycoerythrin was
added for 30 minutes. Fluorescent emissions distinct to each
growth factor/cytokine were simultaneously measured using
the BioPlex Detection System, and the resulting data were
analyzed using BioPlex software version 4.1 (Bio-Rad).
Growth factor/cytokine concentrations were determined on
the basis of standards run in parallel.
Vitreous from each eye was quantiﬁed separately and
then compiled into groups (RV, nZ 12; RV-PVR, nZ 12;
and RV-VTr, n Z 8) for statistical analysis. The levels of
PDGF-D, GM-CSF, IL-9, IL-10, TNF-a, TNF-b, and
PDGF-D were lower than detection (<0.1 ng/mL), although
this was not due to nonecross-reactivity with the rabbit
growth factor/cytokine ortholog, as ruled out by conﬁrming
the detection of these rabbit proteins in degranulated rabbit
blood or in primary rabbit cells (RCFs).
Western Immuoblot Analysis
After treatment and conditioning, cells were washed twice
with ice-cold phosphate-buffered saline (PBS) and then lysed
in sample buffer (50 mmol/L Tris-HCl, pH 6.8, 10% glycerol,
2% SDS, 1% b-mercaptoethanol, 10 mmol/L EDTA, and
0.02% bromophenol blue) for 15 minutes on ice. Total cell
lysates (TCLs) were heated to 95C for 5 minutes, clariﬁed3056by centrifugation at 14,000  g for 15 minutes at 4C, and
then run on 10% acrylamide SDS-PAGE gel. Electropho-
retically resolved proteins were transferred to polyvinylidene
diﬂuoride membranes by semidry transfer, blocked, and
blotted with the appropriate detection and loading control
antibodies (Table 1). The enhanced chemiluminescent sub-
strate used with horseradish peroxidase detection (via
horseradish peroxidase a-IgG) (Table 1) was from Pierce
Research (Rockford, IL). Each immunoblot area shown is
representative of at least three independent experiments.
Immunoblot signals were captured and analyzed by scanning
densitometry in conjunction with Quantity One software
version 4.6 (Bio-Rad). Experimental signal intensities were
adjusted for background and loading (on the basis of signal
intensity of the loading control), and then normalized to the
negative control in the experiment (or otherwise the signal
expected to be the lowest), which is arbitrarily assigned a
value of 1. Where immunoblot signals were quantiﬁed,
normalized values are given underneath them.
Cell Viability Assays
Determination of Cell Proliferation
ARPE-19a cells were seeded onto 12-well plates at 10,000
cells per well in the appropriate serum-supplemented culturing
media and allowed to attach overnight. The next morning,
media were replaced with serum-free DMEM, supplemented
with either vehicle or the indicated treatments. Media plus
supplements were replaced daily. At 96 hours (4 days), viable
cells from each plate were counted with a hemocytometer.
Experiments were performed independently three times.
Detection of Apoptotic or Senescent Cells
Cells (ARPE-19a or RPEMs) were seeded onto 24-well
plates with coverslips at 5000 ARPE-19a or 10,000 RPEM
cells per well in the appropriate serum-supplemented
culturing media and allowed to attach overnight. The next
morning, media were replaced with DMEM for 24 hours to
induce cell cycle exit (quiescence) by serum deprivation.
Wells were then replaced with fresh serum-free medium
(DMEM) supplemented with vehicle or the indicated treat-
ments. Media plus supplements were replaced every 24 hours
for the next 72 hours. After a total of 96 hours (4 days), cells
were washed with PBS to remove debris and dead cells,
replaced with fresh serum-free DMEM, and immediately
subjected to either of the following: terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labeling
(TUNEL) analysis for detection of apoptotic cellsdusing the
Promega apoptosis detection system (Promega, Fitchburg,
WI), as previously described14dor cytochemical detection
of senescence-associated (SA)eb-galactosidase activity
(AppliChem, St. Louis, MO) for the detection of senescent
cells, as previously described.42 The percentage of apoptotic
cells, determined under the ﬂuorescent microscope, was
calculated as the number of TUNEL-positive nuclei cells/the
total number of viable, DAPI-stained nuclei in the same ﬁeld.ajp.amjpathol.org - The American Journal of Pathology
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ﬁelds, each at 100 magniﬁcation, were analyzed. The per-
centage of senescent cells was determined as the number of
blue staining cells (SAeb-galactosidase positive)/the total
number of cells in the same ﬁeld. In each experiment, a
minimum of 12 randomly chosen ﬁelds, each at 100
magniﬁcation, were analyzed.
Absolute Quantiﬁcation of Receptors by RT-PCR
Standard curves for absolute RT-PCR quantiﬁcation were
generated as follows. T7 RNA polymerase (Life Technolo-
gies, Woburn, MA) was used to generate homogenous pools
of complementary RNA (cRNA) transcripts from puriﬁedFigure 2 Aﬂibercept safely and effectively prevents experimental proliferativ
model. A: Aﬂibercept treatment prevents PVR in rabbits injected with ARPE-19a c
rich plasma (PRP), immediately followed by injection of aﬂibercept into 12 rabbit
12 rabbits (triangles). Rabbits received an additional injection of aﬂibercept or
multiple time points using an indirect ophthalmoscope and fundus lens (days 1 an
PVR was graded using the Fastenberg 5-stage scale.34 One rabbit in the aﬂibercept
of the experiment. B: Fundus photographs of an IgG-injected rabbit eye over prog
days 14, 21, and 28, respectively). C: Aﬂibercept treatment preserves retinal func
injected rabbits (PVR stage 5) and three aﬂibercept-injected rabbits (PVR stage
Aﬂibercept-treated rabbit eyes elicit the same ERG response as their noninjected co
Additional photopic (light-adapted) ERG responses are shown in Supplemental F
acteristics. The same eyes used for ERG in B were ﬁxed, divided into sections, a
intact neural retinas and RPEs with no sign of morphological disruption. IgG-treate
The top half of the IgG-injected panel shows a region of adjacent epiretinal m
pigmented cells; asterisk indicates the site in the middle panel where the ERM
treated section is shown in Supplemental Figure S1C. *P < 0.01 between VEGF
component; b, b-wave component; GCL, ganglion cell layer; INL, inner nuclear l
nuclear layer; OPL, outer plexiform layer; OS, outer segment of the PRL; PRL, pho
The American Journal of Pathology - ajp.amjpathol.orgpGEM (3.0-kB) plasmids containing cDNA sequence inserts
corresponding to human mRNA for PDGFRa (NM_006206),
VEGFR2 (AF063658), or VEGFR1 (AF063657). The cRNA
products were puriﬁed from in vitro transcription mixes using
RNeasy Mini Kit (Qiagen, Valencia, CA) and quantiﬁed by
UV absorbance at 260 nm. RNA concentrations were con-
verted to copy number for each transcript using that tran-
script’s molecular weight, and equal copy numbers for each
transcript were diluted 1:100 with unrelated tRNA from
baker’s yeast (Sigma-Aldrich, St. Louis, MO) to mimic the
heterogeneous background of experimental samples. Three
separate cRNA dilution series were prepared in duplicate over
ﬁve orders of magnitude (spanning 105- to 1010-fold di-
lutions), and then subjected to RT-PCR ampliﬁcation, alonge vitreoretinopathy (PVR) in the retinal pigment epithelial (RPE)-injection
ells. PVR was induced by intravitreal injection of ARPE-19a cells in platelet
s (pentagons) or the same molar amount of normal rabbit IgG into another
IgG at day 21. Eyes were examined and scored for development of PVR at
d 49 shown here) (Supplemental Figure S1A shows additional time points).
group developed a cataract on day 21 and was excluded from the remainder
ressively worsening stages of PVR (stages 2, 4, and 5 PVR images, taken on
tion. Scotopic (dark-adapted) ﬂash electroretinograms (ERGs) of three IgG-
0) were taken on day 47; a representative ERG is shown from each group.
ntralateral eyes, whereas control (IgG) injected eyes show no ERG response.
igure S1B. D: Aﬂibercept treatment preserves retinal morphological char-
nd stained with H&E. Both noninjected and aﬂibercept-injected eyes show
d eyes (PVR stage 5) have convoluted retinas that are completely detached.
embrane (ERM), containing both pigmented cells (RPE derived) and non-
is contiguous with the detached retina. The complete image for the IgG-
-Tr and IgG/mock-treated groups (Mann-Whitney analysis, A). a, a-wave
ayer; IPL, inner plexiform layer; IS, inner segment of the PRL; ONL, outer
toreceptor layer; Vit, vitreous side of the retina.
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Pennock et alwith unknowns and controls (described below). For each
standard, average CT values were determined from each
dilution series and used to generate a standard curve, from
which absolute copy number could be interpolated using CT
values determined for each unknown.
Approximately 2.5 mg of total RNA was extracted from
approximately 2  105 cells for each cell type analyzed:
ARPE-19a, RPEM, HCFs (primary HCFs), and HUVECs
(primary HUVECs). RNAwas extracted using TRIzol reagent
(Invitrogen, Carlsbad, CA) and quantiﬁed by UV absorbance,
as described above. The cDNAwas generated using an iScript
cDNA synthesis kit (Bio-Rad), according to the manufac-
turer’s instructions. The resulting cDNA product (1 mL) was
subjected to real-time PCR ampliﬁcation alongside standards
and controls using the SYBR Green system in conjunction
with a 96-well plate Lightcycler (Roche, Branford, CT). For-
ward and reverse PCR primers corresponded to each receptor
cDNA and each primer pair designed or chosen to generate
amplicons of similar size to each other. PDGFRa mRNAFigure 3 Aﬂibercept safely and effectively prevents experimental proliferati
injection of aﬂibercept prevents PVR in rabbits injected with rabbit conjunctiv
immediately followed by injection of aﬂibercept (pentagons) or the same molar a
PVR on day 0). Only 9 of 11 rabbits were analyzed in the IgG control group becaus
postinjection and graded for PVR using the Fastenberg 5-stage scale at days 1 an
function. Scotopic (dark-adapted) ﬂash ERGs of IgG-injected rabbits (PVR stage
representative ERG is shown from each group. Data shown are representative of all
are shown in Supplemental Figure S2B. C: Aﬂibercept treatment preserves retinal m
into sections, and stained with H&E. Images of both noninjected and aﬂibercept
sign of morphological disruption. IgG-treated eyes have detached, convoluted reti
containing nonpigmented and pigmented cells. *P < 0.01 between VEGF-Tr and
component; b, b-wave component; GCL, ganglion cell layer; INL, inner nuclear l
nuclear layer; OPL, outer plexiform layer; OS, outer segment of the PRL; PRL, pho
3058primers (sense, 50-TGGGAGGGTGGTCTGGATGAG-30;
antisense, 50-GATGAAGGTGGAACTGCGGGAAC-30),
VEGFR2 mRNA primers (sense, 50-CACCACTC-
AAACGCTGACATGTA-30; antisense, 50-GCTCGTTGG-
CGCACTCTT-30), and VEGFR1 mRNA primers (sense,
50-GTCACAGAAGAGGATGAAGGTGTC-30; antisense,
50-CACAGTCCGGCACGTAGGTGATT-30) were used.
A negative no template control was run to exclude contami-
nation of buffers, primers, and enzymes. Real-time PCR
ampliﬁcation was performed as follows: 50C for 2 minutes
once/ 95C for 10 minutes once; then 30 cycles of 95C for
15 seconds/ 60C for 30 seconds (annealing temperatures of
all primers were the same)/ 72C for 45 seconds; then 72C
for 10minutes on the last cycle.A30-cycle limitwas established
on the basis of ampliﬁcation of nonsense products in the no
template control. Dissociation curve analysis was performed,
and real-time PCRdatawere analyzedwithAppliedBiosystems
7000 SDS software verison 1.4.1; no bimodel dissociation or
abnormal ampliﬁcation was observed. Transcript abundancesve vitreoretinopathy (PVR) in the ﬁbroblast-injection model. A: A single
al ﬁbroblasts (RCFs). PVR was induced by intravitreal injection of RCFs,
mount of normal rabbit IgG (triangle; simultaneously with the induction of
e of complications unrelated to the experiment. Rabbit eyes were examined
d 28 (Supplemental Figure S2A). B: Aﬂibercept treatment preserves retinal
4) and aﬂibercept-injected rabbits (PVR stage 0) were taken on day 26; a
rabbits in each treatment group measured (nZ 3). Photopic ERG responses
orphological characteristics. The same eyes for ERG in B were ﬁxed, divided
-injected eyes show intact neural retinas with some associated RPE and no
nas. The top half of the IgG-injected panel shows a region of adjacent ERM,
IgG/mock-treated groups at day 28 (Mann-Whitney analysis, A). a, a-wave
ayer; IPL, inner plexiform layer; IS, inner segment of the PRL; ONL, outer
toreceptor layer; Vit, vitreous side of the retina.
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VEGF Acts via PDGFRa to Promote PVRinterpolated from standard-curve CT values are expressed as
absolute receptor mRNA copy number per 100 ng of total RNA
(100 ng total RNA approximates 5000 to 10,000 cells).
Meta-Analysis of Patient Vitreous
Human PVR vitreous samples (n Z 36) that had been
previously proﬁled14,24 were recompiled into traumatic and
non-traumatic categories and compared with experimental
PVR vitreous proﬁles to identify a core set of growth fac-
tors/cytokines that putatively constitute PVR bioactivity in
both rabbits and humans.
Collagen Gel Contraction Assay
As a surrogate model for ERM contraction during PVR, cell-
mediated collagen gel contraction was assayed, as described
previously.14,24 Brieﬂy, RPEMs were starved and precondi-
tioned for 24 hours with the indicated treatment before being
harvested and suspended at 1  106 cells/mL in a solution
containing 1.5 mg/mL neutralized collagen I (INAMED,
Fremont, CA) at pH 7.2 plus the same indicated treatment.
Cell suspensions were then transferred at 0.1 mL/well into
24-well plates that had been preincubatedwith PBS and 5 mg/mL
bovine serum albumin for a minimum of 4 hours. After
polymerization of the collagen gel at 37C after 60 to 90
minutes, 24 wells were overlaid with 0.5 mL serum-free
DMEM supplemented with nothing or the indicated treat-
ment (same as above). Media plus supplements were replacedFigure 4 Vascular endothelial growth factor (VEGF)-Tr attenuates vitreous-driv
TP53 reduction in ARPE-19a cells depends on endogenous VEGF. ARPE-19a cells w
the indicated type of vitreous. After treatment, cells were lysed and the resulting t
antibodies. The signal intensity of the resulting immunoblots was quantiﬁed by
stimulated cells are shown under the immunoblot. The data presented are repres
to protect from starvation-induced apoptosis in retinal pigment epithelial cells de
to induce quiescence, and then incubated an additional 72 hours in the same star
Media plus supplements were replaced daily. After a total of 96 hours, cells were w
represent the means  SD of three independent experiments. In each experiment,
analyzed. C: PVR vitreous-driven protection from starvation-induced senescence in
and treated as in B. Senescent cells were quantiﬁed using phase-contrast micros
SAeb-galactosidaseepositive cells/the total number of viable cells in the same
at 100 magniﬁcation) were analyzed. D: The ability of PVR vitreous to drive proli
starved and treated as in B. The graph compiles data from three independent exper
to the number of cells initially seeded. Cell growth differs signiﬁcantly between s
differences occur between any of the vitreous-supplemented cells. The data show
Data were compared using a paired t-test. *P < 0.05. RV, healthy vitreous isolate
with PVR stage 5; and RV-VTr, vitreous isolated from VEGF-Tr/aﬂibercept-injected
The American Journal of Pathology - ajp.amjpathol.orgevery 24 hours for the next 72 hours. Collagen gel area was
measured at 96 hours to determine percentage contraction,
calculated as follows:
100  ðarea of gel at 96 h = area of gel at 0 hÞ: ð1Þ
At 0 hour, the diameter of each gel equals the diameter of the
well. Values are reported as the mean % contraction  SD,
obtained from at least three independent experiments (each
performed in triplicate).
Statistical Analysis
Datawere analyzed throughout this study using unpaired t-tests
and one-way analysis of variance by Mann-Whitney analysis
post hoc test using Sigmaplot 5 (Systat Software Inc., Chicago,
IL). P < 0.05 was considered statistically signiﬁcant.
Results
Aﬂibercept Safely and Effectively Prevents PVR in Two
Experimental Models
In light of our previous preclinical studies validating rani-
bizumab as a prophylactic for experimental PVR,14 we
considered if other approaches to neutralize VEGF were
also effective. To this end, we focused on aﬂibercept in two
models of PVR. Aﬂibercept is a VEGF trap that includes
portions of the extracellular domain of both VEGFR1 and
VEGFR2; it is, therefore, capable of neutralizing all VEGFen cell viability associated with TP53. A: The ability of PVR vitreous to drive
ere serum starved and either left untreated (----) or treated for 2 hours with
otal cell lysates were subjected to Western blot analysis using the indicated
densitometry, and ratios representing band intensities normalized to non-
entative of three independent experiments. B: The ability of PVR vitreous
pends on endogenous VEGF. ARPE-19a cells were serum starved for 24 hours
vation medium supplemented with nothing (----) or the indicated vitreous.
ashed and subjected to apoptosis detection assay by TUNEL. The data shown
a minimum of 10 randomly chosen ﬁelds, each at 100 magniﬁcation, were
ARPE-19a cells depends on endogenous VEGF. ARPE-19a cells were starved
copy. The percentage of senescent cells was determined as the number of
ﬁeld. In each experiment, a minimum of 12 randomly chosen ﬁelds (each
feration of ARPE-19a cells occurs independent of VEGF. ARPE-19a cells were
iments, where each bar is the mean  SD increase in cell number normalized
tarved cells and those supplemented with vitreous, although no signiﬁcant
n in BeD represent the means  SD from three independent experiments.
d from noninjected eyes; RV-PVR, vitreous isolated from IgG-injected eyes
eyes with PVR stages 0 to 1.
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Pennock et al(VEGF-A) isoforms, VEGF-related proteins (VEGFs B, C,
and D), and placenta growth factor.43,44
Retinal pigment epithelial (RPE) cells abound in ERMs
from patients with PVR, and injecting these cells into vit-
reous of rabbits induces PVR.30,45 We tested if aﬂibercept
prevents PVR in rabbits that were injected with ARPE-19a
cells, which is an RPE cell line engineered to overexpress
PDGFRa; consequentially, ARPE-19a cells induce PVR
more aggressively than parental ARPE cells.30
Injection of ARPE-19a cells induced RD (stage 3 or
higher) in 12 (100%) of 12 animals (Figure 2A). In contrast
to this IgG-injected control group, only 3 (27%) of 11
aﬂibercept-injected rabbits developed RD (Figure 2A).
Supplemental Figure S1A includes the clinical status of
rabbits over additional time points spanning the entire
7-week experimental time course. Fundus images from a
single IgG-injected rabbit typify the progression to complete
RD observed in this model (Figure 2B). These results
indicate that aﬂibercept prevented RD in most rabbits.
We examined the ability of aﬂibercept to preserve retinal
function in this animal model of PVR. The scotopic ﬂash
ERGs in Figure 2C (representative of three independently
measured rabbits for each group) show that PVR abolished
retinal function, whereas aﬂibercept prevented this outcome.
Furthermore, comparison of the scotopic ﬂash ERG data
from noninjected and aﬂibercept-injected eyes demonstrates
that aﬂibercept itself did not compromise the functional
integrity of the retina (Figure 2C). These same conclusionsFigure 5 Neutralizing vascular endothelial growth factor (VEGF) does not g
etinopathy (PVR) vitreous. Vitreous isolated from retinal pigment epithelial (RPE
analysis to quantify 26 growth factors or cytokines associated with PVR.18,24,41 Th
ng/mL) and, thus, omitted from the bar graph: platelet-derived growth factor-D (P
IL-10, TNF-a, and TNF-b. Only the active forms of the three TGF-b isoforms were
growth factor (IGF)-1, and connective tissue growth factor (CTGF) were quantiﬁ
ﬁed by multiplex analysis. The anti-CTGF antibody recognizes both N- and C-termin
SDs. The growth factor and cytokine proﬁle for the ﬁbroblast-injection model of P
with RV-PVR. *P < 0.05, RV-PVR to RV-VTr; yP < 0.05. RV, healthy vitreous isolat
with PVR stage 5; and RV-VTr, vitreous isolated from VEGF-Tr/aﬂibercept-injected
3060emerged from consideration of additional modes of ERG
response (Supplemental Figure S1B). Thus, aﬂibercept
safely and effectively prevented the PVR-associated loss in
retinal function, likely because it prevented RD (Figure 2A),
which triggers TP53-associated death of neural retinal cells
due, in part, to loss of metabolic and nutritional support
from the underlying RPE layer.46e49
Next, we examined the ability of aﬂibercept to preserve
retinal structure in our present experimental model. Both an
RPE-rich ERM and a highly disordered neural retina were
prominent features of eyes that developed PVR (Figure 2D
and Supplemental Figure S1C). In contrast, the layers of
neural retinal cells in aﬂibercept-injected eyes were overtly
normal (Figure 2D). These results suggest that aﬂibercept
prevents PVR after RPE injection and thereby preserved
retinal function and morphological features in most of the
rabbits that received this treatment.
We repeated the experiments using a second model of
PVR in which RCFs were injected instead of ARPE-19a
cells with similar results. Aﬂibercept prevented RD in 11
(100%) of 11 animals (Figure 3A and Supplemental
Figure S2A), halted the associated abrogation of retinal
function (Figure 3B and Supplemental Figure S2B), and
deterred the development of an ERM and the concomitant
morphological disorganization of the retina (Figure 3C and
Supplemental Figure S2C). Although PVR was induced by
injection of nonpigmented ﬁbroblasts, the ERM contained
an abundance of pigmented cells (Figure 3C andlobally diminish growth factor levels in experimental proliferative vitreor-
)-injected rabbits was analyzed by multiplex or quantitative Western blot
e following growth factors and cytokines were lower than detection (<0.1
DGF-D), granulocyte macrophage colony-stimulating factor (GM-CSF), IL-9,
quantiﬁed. PDGF-C, PDGF-D, hepatocyte growth factor (HGF), insulin-like
ed by using Western blot analysis, whereas all other factors were quanti-
al CTGF fragments. The bars represent the means, whereas error bars indicate
VR has been published elsewhere.24 Paired t-tests were used to compare RV
ed from noninjected eyes; RV-PVR, vitreous isolated from IgG-injected eyes
eyes with PVR stages 0 to 1, were proﬁled.
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VEGF Acts via PDGFRa to Promote PVRSupplemental Figure S2C). Such an observation suggests
that resident pigmented cells (eg, RPE) contribute to the
formation of an ERM, even though they were not among the
cells that instigated disease.
Taken together, the results from Figures 2 and 3 demon-
strate that aﬂibercept suppresses PVR in two models of dis-
ease without adversely affecting retinal function or structure.
Aﬂibercept Reduces the Ability of Vitreous to Promote
Viability of Cells
Components of the vitreous drive several cellular responses
related to PVR, and these abilities are associatedwith a decline
in the level of TP53.11,12,14,24 These observations predict that
vitreous from aﬂibercept-injected animals would be less
capable of reducing TP53 and promoting PVR-associated
cellular responses compared with vitreous from IgG-
injected animals, thus leading to elevated TP53-associated
fates, including cell cycle arrest, apoptosis, and senes-
cence.13,50 Indeed, we observed that RV-PVR (vitreous from
IgG-injected rabbits) more efﬁciently suppressed TP53 and
protected ARPE-19a cells from apoptosis and senescenceThe American Journal of Pathology - ajp.amjpathol.orgthan RV-VTr (vitreous from aﬂibercept-injected rabbits)
(Figure 4, AeC). In contrast, there was no signiﬁcant differ-
ence in the ability of RV-PVR and RV-VTr to stimulate cell
proliferation (Figure 4D). These ﬁndings indicate that aﬂi-
bercept reduced the ability of vitreous to protect cells from
apoptosis and senescence, and that this phenomenon was
associatedwith its reduced ability to depress the level of TP53.The Relationship between VEGF, PDGFs, and Non-PDGFs
Determines the Bioactivity of RV-PVR
We ﬁrst considered a straightforward explanation for why
aﬂibercept eliminated the bioactivity of vitreous from
ARPE-19aeinjected rabbits (namely, because it globally
reduced the level of non-PDGFs, many of which are
required for PVR).24 Figure 5 shows the proﬁle of growth
factors and cytokines in vitreous from IgG- and aﬂibercept-
injected rabbits (RV-PVR and RV-VTr, respectively).
Although VEGF was not the only growth factor that was
lower in RV-VTr versus RV-PVR vitreous, it was clear thatFigure 6 Noneplatelet-derived growth factors (non-PDGFs) and
vascular endothelial growth factor (VEGF) are necessary for the bioactivity of
proliferative vitreoretinopathy (PVR) vitreouseinduced TP53 reduction in
ARPE-19a cells. A: Cells were starved and then either left untreated (----) or
treated for 2 hours as indicated in the presence of RV-PVR or GFs-PVR
(comprising 16 recombinant human growth factors corresponding to the
core set identiﬁed in Table 2). Treatments included 10 mg/mL of nonimmune
IgG (IgG), a mixture of neutralizing antibodies directed against the 13 non-
PDGFs included in GFs-PVR (a-nonPs), an equimolar mixture of neutralizing
antibodies against all PDGF agonists of PDGFRa (a-PDGFs), or 250 mg/mL of
aﬂibercept/VEGF-Trap (VEGF-Tr). After treatment, cells were lysed and the
resulting total cell lysates (TCLs) were subjected to Western blot analysis
using the indicated antibodies. The signal intensity of the resulting immu-
noblots was quantiﬁed by densitometry, and ratios representing band in-
tensities normalized to non-stimulated cells are shown under the
immunoblot. B: Non-PDGFs and VEGF were necessary for PVR vitreouse
induced protection from apoptosis in ARPE-19a cells. Cells were starved 24
hours and then administered the same treatments as in A, except treatment
was maintained for 72 hours instead of 2 hours; starvation media plus
supplements were replaced daily. At 96 hours, cells were subjected to TUNEL
analysis. The data shown represent the means  SD of three independent
experiments. Data were compared using a paired t-test. C: Non-PDGFs and
VEGF are necessary for PVR vitreouseinduced protection from senescence in
ARPE-19a cells. Cells were starved and treated as in B. At 96 hours, the
percentage of senescent cells was determined. The data shown represent the
means  SD from three independent experiments, and were statistically
compared as in B. VEGF promotes vitreous-induced reduction of TP53 by
counteracting vitreal PDGFs. ARPE-19a cells were starved and then either left
untreated (----) or treated for 2 hours as indicated in the presence of RV-PVR
or RV-VTr. Treatments included 10 mg/mL of nonimmune IgG (IgG), 250 mg/
uL of aﬂibercept/VEGF-Trap (VEGF-Tr), an equimolar mixture of neutralizing
antibodies against all PDGF agonists of PDGFRa (a-PDGFs), a combination of
VEGF-Tr and a-PDGFs (same concentrations used individually), a super-
saturating dose of 500 ng/mL PDGF-A (þPDGF-A), or 20 ng/mL of VEGF
(VEGF-A). After treatment, treated cells were lysed and the resulting TCLs
subjected to Western blot analysis using the indicated antibodies. The signal
intensity of the resulting immunoblots was quantiﬁed by densitometry, and
ratios representing band intensities normalized to non-stimulated cells are
shown under the immunoblot. *P < 0.05. RV, healthy vitreous isolated from
noninjected eyes; RV-VTr, vitreous isolated from VEGF-Tr/aﬂibercept-
injected eyes with PVR stages 0 to 1.
3061

















VEGF þ þ þ þ þ þ þ
PDGF-A þ þ þ þ þ
PDGF-AB þ þ þ  þ
PDGF-B þ þ  
PDGF-C þ þ þ þ þ þ þ þ þ þ þ þ
CTGF þ þ þ þ þ þ þ þ þ
EGF þ þ  þ
FGF-2 þ þ þ þ þ þ
G-CSF  þ  þ
HGF þ þ þ þ þ þ
IFN-g þ þ þ þ  þ þ
IGF-1 þ þ þ þ þ þ
IL-6  þ þ þ þ
MCP-1  þ þ þ þ þ
TGF-a þ þ þ þ þ
TGF-b1 þ þ þ  þ
TGF-b2 þ þ þ þ þ þ
TGF-b3 þ þ  þ
Proﬁling data from two models of experimental PVRdthe RPE-injection
model (Figure 5) and the ﬁbroblast-injection model24dtogether with
clinical proﬁles from the vitreous of PVR patients,24 which is subdivided
into traumatic and non-traumatic categories. All growth factors and cy-
tokines listed are present in at least one type of vitreous from each species,
and identify a core set of factors that putatively constitute PVR bioactivity
in both experimental and clinical vitreous.
*The following three groups of growth factors and cytokines were omitted
from this table: i) PDGF-D, GM-CSF, IL-9, and IL-10, each of which were lower
than detection in all four types of vitreous (this was not due to a failure to
detect the rabbit and/or human orthologs, as all four agents were detectable
when tested in cells and/or serum from either species, data not shown); ii)
IL-1b and IL-8, which were present (within the 0.1 to 2.5 ng/mL range) only
in rabbit vitreous; and iii) TNF-a and TNF-b, which were present (within the
0.1 to 2.5 ng/mL range) only in traumatic human PVR vitreous. PDGF-B was
detectable only in rabbit vitreous, although it was included as part of the core
set because the presence of PDGF-AB in human vitreous suggests that some
PDGF-Bmight exist; by including PDGF-B as part of the core set, we are able to
ensure that all direct agonists of PDGFRa in vitreous are accounted for.
yThe þ andL symbols indicate the concentration range at which growth
factors and cytokines were present in each type of vitreous.
þ, 0.1 to 2.5 ng/mL; þþ, 2.5 to 10 ng/mL; þþþ, >10 ng/mL; , <0.1
ng/mL (considered lower than detection).
Pennock et alaﬂibercept had not globally suppressed the level of growth
factors and cytokines. Furthermore, the growth factors and
cytokines in RV-VTr should be enough to constitute the
bioactivity of vitreous, because their levels were higher than
many growth factors and cytokines in the vitreous from
healthy rabbits (RV) (Figure 5), and RV is fully capable of
reducing TP53 and promoting viability (Figure 4). Conse-
quently, these proﬁling data do not support the explanation
that aﬂibercept reduced the bioactivity of vitreous by
causing a universal reduction in the level of growth factors
and cytokines in vitreous.
Our previous ﬁndings, summarized in Figure 1, offer an
alternative explanation; eliminating VEGF with aﬂibercept
unleashed the antagonistic action of PDGF on nonePDGF-
mediated indirect activation of PDGFRa, which drives
signaling events and cellular responses associated with
PVR.12,24 Neutralizing either non-PDGFs or VEGF signiﬁ-
cantly eliminated the ability of RV-PVR to suppress TP53 and
protect ARPE-19a cells from apoptosis and senescence
(Figure 6, AeC). Furthermore, neutralizing PDGFs had no
impact on the bioactivity of RV-PVR (Figure 6, AeC), even
though they were present at a concentration sufﬁcient to drive
signaling events and cellular responses (>20 ng/mL)
(Figure 5). Similar results were seen from experiments in
which puriﬁed growth factors were used instead of vitreous
(Figure 6, AeC), indicating that all of the relevant contributors
have been identiﬁed. The selection of growth factors and cy-
tokines to include in these studies, as well as their concentra-
tions, was on the basis of vitreous proﬁling data from two
different animal models and patient donors (Table 2).
If the reason that aﬂibercept reduced the bioactivity of
vitreous was because it derepressed PDGFs, then neutral-
izing PDGFs should overcome the effect of aﬂibercept.
Indeed, the aﬂibercept-mediated change in the level of TP53
was substantially reduced when PDGFs were neutralized
(Figure 6D). The same type of result was observed when
PDGFs were neutralized in vitreous from rabbits that had
been injected with aﬂibercept (RV-VTr) (Figure 6D).
Finally, because the relationships shown in Figure 1 are
competitive, increasing the concentration of PDGF should
lower the bioactivity of vitreous. The ability of RV-PVR to
reduce TP53 was suppressed by elevating PDGF-A
(Figure 6D). We conclude that the bioactivity of vitreous
from rabbits that developed PVR after injection of ARPE-
19a cells is governed by the functional relationship among
three classes of growth factors (Figure 1).
VEGF-Dependent Activation of VEGFRs Contributes
Minimally to the Bioactivity of PVR Vitreous
Because VEGF promotes viability of VEGFR-expressing
cells,51,52 which include ARPE-19a (Figure 7A), VEGF-
mediated promotion of indirect PDGFRa activation by
non-PDGFs (Figure 1) may not be the only way that VEGF
contributes to the bioactivity of RV-PVR. It may also
participate by the canonical route, which involves3062activation of VEGFRs. To investigate this issue, we
stimulated ARPE-19a cells with puriﬁed VEGF and
measured PVR-associated signaling events and cellular
responses. VEGF was unable to suppress the level of TP53
or prevent senescence (Figure 7, B and D), although it
protected cells from apoptosis (Figure 7C). Thus, VEGF
was sufﬁcient for certain outcomes, albeit with reduced
efﬁciency, even when used at an approximately threefold
higher dose than what was present in RV-PVR (Figure 5).
To test the relative contribution of VEGF-dependent acti-
vation of VEGFRs to the overall bioactivity of RV-PVR,
we assayed the effect of pharmacologically blockingajp.amjpathol.org - The American Journal of Pathology
Figure 7 Vascular endothelial growth factor (VEGF)-dependent activation of VEGF receptors (VEGFRs) contributes minimally to the bioactivity of
proliferative vitreoretinopathy (PVR) vitreous. A: RT-PCR quantiﬁcation of VEGFR2, VEGFR1, and platelet-derived growth factor alpha (PDGFRa) expression
in human ARPE-19a cells, primary human corneal ﬁbroblasts (HCFs), and primary human umbilical vascular endothelial cells (HUVECs). Resulting data show
absolute mRNA copy number per 100 ng of total RNA, and were determined on the basis of comparison to standard curves using puriﬁed plasmids for each
receptor type. ARPE-19a expresses both VEGFRs and PDGFRas (the latter is overexpressed), whereas HCFs and HUVECs express only PDGFRa or VEGFRs,
respectively. B: The kinase activity of VEGFRs expressed on ARPE-19a cells does not contribute to vitreous-induced reduction of TP53. Cells were starved
and treated in parallel for 10 minutes (to assess VEGFR activation) or 2 hours (to assess TP53 reduction) with no treatment (----), 20 ng/mL VEGF, or RV-PVR
in either the absence (--) or presence (þ) of yrosine kinase inhibitor (VR-inh), which was added 30 minutes before treatment and used at a concentration
of 360 nmol/L, sufﬁcient to neutralize both VEGFR isoforms.28 After treatment, cells were lysed and subjected to Western blot analysis using the indicated
antibodies. The signal intensity of the resulting immunoblots was quantiﬁed by densitometry, and ratios representing band intensities normalized to non-
stimulated cells are shown under the immunoblot. C: Vitreous VEGF protects from apoptosis through its canonical ability to activate VEGFRs and its
noncanonical ability to promote indirect activation of PDGFRa. ARPE-19a cells were starved and treated as in B, except treatment was maintained for 72
hours instead of 2 hours, with starvation media plus supplements replaced daily, including VR-Inh. At 96 hours, cells were subjected to TUNEL analysis. The
data shown represent the means  SD of three independent experiments. Data were compared using a paired t-test. D: Vitreous VEGF protects from
senescence primarily by its noncanonical ability to promote indirect activation of PDGFRa. ARPE-19a cells were starved 24 hours and then treated as in C.
The percentage of senescent cells was determined at 96 hours. The data shown represent the means  SD from three independent experiments, and were
statistically compared as in C. *P < 0.05. DMSO, dimethyl sulfoxide.
VEGF Acts via PDGFRa to Promote PVRVEGFRs on RV-PVRetriggered responses. There was no
impact on suppression of TP53 (Figure 7B), and a modest
and statistically signiﬁcant decline in RV-PVRemediated
protection from apoptosis and senescence (Figure 7, C and
D). Thus, the VEGFR-associated canonical action of
VEGF makes a minor contribution to the bioactivity of
RV-PVR. Put another way, most of VEGF’s contribution
to the bioactivity of vitreous appears to be via PDGFRa
instead of VEGFR (Figure 1).
Aﬂibercept Neutralizes the Bioactivity of Vitreous from
Patients with PVR
We previously reported that three classes of growth fac-
tors are present in vitreous from patients with PVR, they
functionally interact as shown in Figure 1, and these re-
lationships determine the bioactivity of such vitreous.14,24The American Journal of Pathology - ajp.amjpathol.orgMore important, ranibizumab substantially reduced the
ability of patient PVR vitreous to drive signaling events
and cellular responses associated with PVR in cells
derived from a donor PVR membrane (RPEM cells).14 In
light of the translational focus of our present study,
similar types of experiments were performed with aﬂi-
bercept (VEGF-Tr) using vitreous from patients with
traumatic PVR (HV-PVR), which contains relatively high
and nearly equimolar levels of VEGF and PDGFs
(Table 2),14 and, thus, is strongly relevant to the para-
digm in Figure 1. Neutralization of non-PDGFs (the same
12 targeted in RV-PVR) or VEGF (aﬂibercept) in HV-
PVR attenuated its ability to reduce TP53 (Figure 8A)
or promote viability of RPEM cells (ie, protect against
apoptosis and senescence) (Figure 8, B and C). Elimi-
nating non-PDGFs, and to a lesser extent VEGF, from
vitreous caused a modest, yet signiﬁcant, decline in3063
Pennock et alHV-PVReinduced contraction of RPEM-embedded
collagen gels (Figure 8D). These cells, unlike ARPE-
19a, are derived from a patient PVR membrane (RPEMs)
and are capable of contracting a collagen matrix, which is
considered a surrogate measure of RD.22,24 As in exper-
imental PVR vitreous, PDGF behaved as an antagonist of
HV-PVR bioactivity; aﬂibercept was overcome by
neutralizing PDGFs, and boosting the level of PDGF-A
attenuated the bioactivity of HV-PVR (Figure 8, AeD).
Taken together, these results indicate that both VEGF and
non-PDGFsdcomprising the 12 present in GFs-PVR3064(Table 2)dare each essential for the bioactivity of vit-
reous from patients with severe PVR.
VEGF Contributes to the Bioactivity of Patient Vitreous
Independent of VEGFR Activity
Our results revealed that although the major determinant of
VEGF’s contribution to the bioactivity of vitreous involved
antagonism of PDGFs, it can also serve this role canonically
by activating VEGFRs. Because RPEM cells have VEGFRs
(Figure 9A), in agreement with other RPE cell lines
(Figure 7A),28 we considered to what extent VEGF-
mediated VEGFR signaling contributed to biological out-
comes in these cells. Puriﬁed VEGF was unable to reduce
the level of TP53 or prevent senescence (Figure 9, B and C),
although it protected RPEM cells from apoptosis
(Figure 9D), and triggered a small, yet signiﬁcant, level ofFigure 8 Vascular endothelial growth factor (VEGF) and noneplatelet-
derived growth factors (non-PDGFs) enhance, whereas PDGFs antagonize,
the bioactivity of vitreous from patients with proliferative vitreoretinopathy
(PVR) after severe trauma. A: Non-PDGFs and VEGF are necessary for vitreous
from patients with PVR after severe trauma (HV-PVR) to reduce TP53 in
retinal pigment epithelial (RPE) cells isolated from a human PVR membrane
(RPEM cells). RPEMs were starved and then either left untreated (----) or
treated for 2 hours as indicated in the presence of HV-PVRdan equal volume
mix of 10 vitreous samples from patients with post-traumatic grade C PVR.
Treatments included 10 mg/mL of nonimmune IgG (IgG), a mixture of
neutralizing antibodies directed against the 13 non-PDGFs included in GFs-
PVR as listed in Table 2 (a-nonPs), an equimolar mixture of neutralizing
antibodies against all PDGF agonists of PDGFRa (a-PDGFs), 250 mg/mL of
aﬂibercept/VEGF-Trap (VEGF-Tr), a combination of VEGF-Trþ a-PDGFs (same
concentrations used individually), and a supersaturating dose of 500 ng/mL
PDGF-A (þPDGF-A). After treatment, cells were lysed and the resulting total
cell lysates were subjected to Western blot analysis using the indicated
antibodies. The signal intensity of the resulting immunoblots was quantiﬁed
by densitometry, and ratios representing band intensities normalized to
non-stimulated cells are shown under the immunoblot. B: Non-PDGFs and
VEGF were necessary for HV-PVR’s ability to protect RPEMs from starvation-
induced apoptosis. RPEMs were starved 24 hours and then administered
the same treatments as in A except treatment was maintained for 72 hours
instead of 2 hours, with starvation media plus supplements replaced daily. At
96 hours, cells were subjected to TUNEL analysis. The data shown represent
the means  SD of three independent experiments. Data were compared
using a paired t-test. Endogenous PDGF contributes a small amount to HV-
PVRedriven contraction; elevating the concentration of PDGFs in HV-PVR
can also drive contraction. Both these results are expected because PDGF
itself can drive contraction,53,54 which is much more apparent at earlier time
points (<4 days, data not shown). C: Non-PDGFs and VEGF are necessary for
HV-PVR’s ability to protect RPEMs from starvation-induced senescence.
RPEMs were starved 24 hours and then administered the same treatments as
in A except treatment was maintained for 72 hours instead of 2 hours, with
starvation media plus supplements replaced daily. The percentage of se-
nescent cells was determined at 96 hours. The data shown represent the
means  SD from three independent experiments, and were statistically
compared as in B. D: Non-PDGFs and VEGF were necessary for RPEM-mediated
collagen gel contraction driven by HV-PVR. RPEMs were starved, precondi-
tioned for 24 hours with the same treatments in A, and then suspended in a
collagen gel and treated an additional 72 hours, with starvation media plus
supplements replaced daily. Gel area was measured at 96 hours to determine
the percentage collagen contraction. Each bar represents a mean  SD
percentage contraction obtained from three independent experiments, and
was statistically compared as in B. *P < 0.05.
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Figure 9 Vascular endothelial growth factor (VEGF)-dependent activation of VEGF receptors (VEGFRs) is dispensable for the bioactivity of vitreous from
patients with proliferative vitreoretinopathy (PVR) after severe trauma. RT-PCR quantiﬁcation of VEGFR2, VEGFR1, and PDGFRa expression in human cells.
Expression in RPEMs, primary human corneal ﬁbroblasts (HCFs), and primary human umbilical vascular endothelial cells (HUVECs). A: Resulting data show
absolute mRNA copy number per 100 ng of total RNA, and were determined on the basis of comparison to standard curves using puriﬁed plasmids for each
receptor type. RPEMs express both VEGFRs and PDGFRas, similar to ARPE-19a (Figure 7A), with the notable exception that PDGFRa is not overexpressed. HCFs
and HUVECs express only PDGFRa and VEGFRs, respectively. B: The kinase activity of VEGFRs expressed on RPEMs does not contribute to vitreous-induced
reduction of TP53. Cells were starved and treated in parallel for 10 minutes (to assess VEGFR activation) or 2 hours (to assess TP53 reduction) with no
treatment (----), 20 ng/mL VEGF, or HV-PVR in either the absence (--) or presence (þ) of a VEGFR tyrosine kinase inhibitor (VR-inh), which was added 30
minutes before treatment and used at a concentration of 360 nmol/L, sufﬁcient to neutralize both VEGFR isoforms.28 After treatment, cells were lysed and
subjected to Western blot analysis using the indicated antibodies. The signal intensity of the resulting immunoblots was quantiﬁed by densitometry, and ratios
representing band intensities normalized to non-stimulated cells are shown under the immunoblot. Neither VEGFR1 nor VEGFR2 kinases are required for HV-
PVRedriven TP53 reduction. C: VEGF-dependent activation of VEGFRs is dispensable for HV-PVR’s ability to protect RPEMs from starvation-induced senescence.
RPEMs were starved and preconditioned for 24 hours with the same treatments in B, except treatment was maintained for 72 hours instead of 2 hours, with
starvation media plus supplements replaced daily. The percentage of senescent cells was determined at 96 hours. The data shown represent the means  SD
from three independent experiments. Data were compared using a paired t-test. D: VEGF-dependent activation of VEGFRs is dispensable for HV-PVR’s ability to
protect RPEMs from starvation-induced apoptosis. RPEMs were starved 24 hours and then administered the same treatments as in B, except treatment was
maintained for 72 hours and media plus any supplements were replaced daily. At 96 hours, cells were subjected to TUNEL analysis. The data shown represent
the means  SD of three independent experiments and were statistically compared as in C. E: VEGF-dependent activation of VEGFRs is dispensable for HV-PVR’s
ability to drive collagen gel contraction containing RPEMs. RPEMs were starved, preconditioned for 24 hours with the same treatments in B, and then
suspended in a collagen gel, after which cells were administered treatment an additional 72 hours, with starvation media plus supplements replaced daily. Gel
area was measured at 96 hours to determine percentage collagen contraction. Each bar represents a mean  SD percentage contraction obtained from three
independent experiments and was statistically compared as in C. *P < 0.05. DMSO, dimethyl sulfoxide.
VEGF Acts via PDGFRa to Promote PVRcollagen gel contraction (Figure 9E). We also tested the
importance of VEGFR activity for the bioactivity of HV-
PVR on RPEM cells. Pharmacologically blocking
VEGFRs had no impact on the level of TP53, contraction,
or viability in response to HV-PVR (Figure 9, B and E).
These studies indicate that the canonical VEGF/VEGFR
axis is dispensable for bioactivity of HV-PVR. Together
with the data shown in Figure 8, we conclude that VEGFThe American Journal of Pathology - ajp.amjpathol.orggoverns the bioactivity of vitreous from patients with trau-
matic PVR by antagonizing PDGFs, thereby enabling in-
direct activation of PDGFRa by non-PDGFs (Figure 1).
Discussion
We found that neutralizing VEGF with aﬂibercept protected
rabbits from PVR in twomodels of disease (Figures 2 and 3)3065
Pennock et aland eliminated PVR bioactivity in both experimental and
clinical vitreous. Furthermore, our data show that VEGF
primarily contributes to PVR bioactivity through its non-
canonical function as an enabler of indirect PDGFRa
activation, despite the existence of two routes (via
VEGFRs or PDGFRa) through which VEGF can promote
PVR-associated events in RPE cells.
Recent publications strongly implicate the TP53 pathway
in the pathogenesis of PVR in our model of PVR and in
patients.11,15,16 Rabbit vitreous-mediated suppression of
TP53 is required for four cellular responses associated with
PVR (protection from apoptosis and senescence, prolifera-
tion, and contraction). Furthermore, preventing the decline
in TP53 protects rabbits from succumbing to PVR.11
However, merely reducing TP53 does not trigger prolifera-
tion or contraction, which indicates that additional vitreous-
driven events are required for these cellular responses.11
Finally, patients with single-nucleotide polymorphisms that
compromise the TP53 pathway have an increased probability
of developing PVR.15,16
Which of the VEGF-neutralizing agentsdaﬂibercept or
ranibizumabdis the better candidate for protecting patients
from PVR? Direct comparison using the same animal model
(Figure 3)14 revealed comparable efﬁcacy in preventing RD
(100% for aﬂibercept and 91% for ranibizumab). Further-
more, neither treatment induced deleterious effects on
retinal function and structure within the study period
(Figure 3 and Supplemental Figure S2).14 Both agents also
eliminated bioactivity in human PVR vitreous by der-
epressing vitreal PDGFs, which is the same mechanism that
governs the bioactivity of rabbit PVR vitreous (Figures 6
and 8).14 We conclude that the efﬁcacy and safety of aﬂi-
bercept and ranibizumab are comparable, and hence both are
suitable candidates for preventing clinical PVR.
Although the focus of this project is on the neutralization
of VEGF, it is possible that the VEGF-related proteins (ie,
VEGFs C, D, and E), also targeted by aﬂibercept and
ranibizumab, somehow contribute to PVR bioactivity.
Although numerous groups have reported that VEGF is
present in PVR vitreous,24,41,55 there are no reports
regarding VEGFs C, D, and E. Of the three, VEGF-E is the
most likely to be present in vitreous because its distribution
is reportedly ubiquitous.56 However, VEGF-E is heat sta-
ble,57 whereas agents that antagonize PDGF in vitreous are
heat labile.28 Additional experimentation is necessary to
directly address if VEGFs C, D, and E are present in PVR
vitreous, and if they contribute to its bioactivity.
When we investigated the growth factor proﬁle of vitre-
ous treated with aﬂibercept (RV-VTr), we were somewhat
surprised to ﬁnd that growth factors other than VEGF had
changed (Figure 5). The decrease in the level of PDGF-A
may result from clearance of PDGF via PDGF-PDGFR
complexes, which would be more prevalent after neutrali-
zation of VEGF (Figure 1). Such an explanation seems
irrelevant for the decline in HGF, CTGF, IL-6, and IL-8, or
the increase in FGF-2. Perhaps the cells responsible for3066producing HGF, CTGF, IL-6, and IL-8 perish as a conse-
quence of aﬂibercept-mediated loss of cell viability. The
similar level of these growth factors in both post-treatment
vitreous (RV-VTr) and healthy vitreous (RV) supports this
explanation (Figure 5). The exception to this is FGF-2,
whose level in healthy vitreous is the same as in PVR vit-
reous, and this points toward an alternate and as of yet
unknown mechanism. VEGF acts noncanonically via
PDGFRa to promote viability of cells. The requirements for
this mechanism include PDGFRa-expressing cells, PDGFs,
and non-PDGFs (Figure 1). In the case of PVR, VEGF is
presumed to promote the viability of cells displaced into the
vitreous. Although this results in pathology, this same
mechanism may be essential for physiology in a different
setting. For instance, noncanonical VEGF action may
contribute to the survival of PDGFRa-positive/VEGFR-
negative cells (pericytes and astrocytes) during hypoxia.
Because the elements of this survival mechanism are present
in a variety of pathological and physiological contexts, it is
possible that the VEGF/PDGF/non-PDGF paradigm extends
beyond PVR pathogenesis.
Conceptually, the VEGF/PDGF/non-PDGF paradigm
(Figure 1) can guide the design of therapies and therapeutic
strategies. In the case of PVRdwhere survival of cells is a
component of pathogenicityda PDGFRa kinase inhibitor
would be predicted to prevent PVR, whereas inhibition of
VEGFR kinase would not. In contrast, antibodies that
neutralize PDGF would have no effect, whereas antibodies
that neutralize VEGF should prevent PVR. By extension,
therefore, simultaneously neutralizing VEGF and PDGF
would be much less effective than neutralizing VEGF alone.
It is particularly bolstering to the integrity of this paradigm
that many of these predictions have turned out to be cor-
rect.14,22,58,59 Overall, these principles are instructive in the
design of therapeutic strategies for preventing PVR, and their
application to additional pathological and physiological set-
tings is an intriguing and as of yet unaddressed question.Acknowledgments
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